Tweenvest Stocks

PepGen Inc. (NasdaqGS: PEPG)

Health Care · Biotechnology · US

$3.23

+7.86% today · +130.0% 1Y

PepGen Inc. (NasdaqGS: PEPG) operates in the Biotechnology industry within the Health Care sector. The company is valued at $207.09M and employs 57 people.

Over the last twelve months the share price has gained 130.0%, trading between 1.13 and 7.80.

Tweenvest scores PepGen Inc. across four factors: quality 26/100. Its strongest factor is quality.

PEPG price history

Not enough price history to draw a chart yet.

Key figures

Market cap
$207.09M
Revenue (TTM)
P/E
EPS
-1.19
Dividend yield
Beta (5Y)
1.89
52-week high
$7.80
52-week low
$1.13
Avg volume (3M)
Shares outstanding
69.26M
Employees
57
Next earnings

About PepGen Inc.

PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.

ISIN
US7133171055
Founded
2018
Listed since
May 6, 2022
Exchange
Nasdaq Global Select
Currency
USD
CompanyMarket capPriceDay
AbbVie Inc.NYSE: ABBV$469.68B$262.85-1.11%
Amgen Inc.NasdaqGS: AMGN$239.09B$440.11-0.48%
Gilead Sciences, Inc.NasdaqGS: GILD$184.47B$148.03-0.50%
Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX$140.13B$549.73-0.56%
Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN$83.24B$818.74-1.78%
argenx SEENXTBR: ARGX$64.17B897.60+2.09%
Moderna, Inc.NasdaqGS: MRNA$63.41B$148.45-6.54%
CSL LimitedASX: CSL$59.49BAU$173.64+2.68%

Browse every Biotechnology company →

Figures last refreshed Aug 18, 2026.